Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
TNT Trial
Introduction
Objective
Objective
To compare the efficacy of 10 mg and 80 mg daily dose of atorvastatin in patients with stable CAD and baseline LDL-C between 130 mg/dL and 250 mg/dL.
Methods
Methods
The Treating to New Targets (TNT) trial was a randomized trial that enrolled 10,001 patients with stable coronary artery disease to treatment with atorvastatin, 80 or 10 mg/dL, and followed them up for a median period of 4.9 years. The primary end point was a composite of cardiovascular death, myocardial infarction, resuscitated cardiac arrest, and stroke.
Results
Results
Compared to low dose, high dose atorvastatin was associated with:
- A significantly lower mean serum LDL-C concentration (77 vs 101 mg/dL)
- Significant reductions in the rate of the primary end point (8.7 vs 10.9 percent)
- No reduction in all-cause mortality. Higher doses of atorvastatin, although reduced mortality due to cardiac events, were associated with higher mortality rate due to noncardiovascular events.
Conclusion
Conclusion
Wider use of the 80-mg dose of atorvastatin in patients with stable coronary disease is safe, cost-effective, and provides an incremental reduction in coronary events.[1]
References
References
- ↑ Waters DD (2009). “Clinical insights from the Treating to New Targets trial”. Progress in Cardiovascular Diseases. 51 (6): 487–502. doi:10.1016/j.pcad.2009.01.001. PMID 19410683.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]